paclitaxel and lcl161
paclitaxel has been researched along with lcl161 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Duan, W; George, J; Hebbard, L; Hu, Z; Lie, S; Qiao, L; Tian, A; Wilson, GS; Wu, G | 1 |
| Chen, Y; Nan, K; Qin, S; Ren, H; Sun, X; Wang, H; Xiao, G; Yang, C; Zhang, B; Zhang, Y | 1 |
| Ando, Y; Kiyota, N; Minami, H; Mitsuma, A; Morita, S; Toyoda, M | 1 |
Trials
1 trial(s) available for paclitaxel and lcl161
| Article | Year |
|---|---|
A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.
Topics: Bayes Theorem; Humans; Inhibitor of Apoptosis Proteins; Japan; Neoplasms; Paclitaxel; Thiazoles; Treatment Outcome | 2022 |
Other Studies
2 other study(ies) available for paclitaxel and lcl161
| Article | Year |
|---|---|
Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Thiazoles | 2014 |
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Middle Aged; Paclitaxel; Prognosis; Proteolysis; Thiazoles; Treatment Outcome; Ubiquitin-Protein Ligases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |